Host tumor cells

Host tumor cells represent the malignant cellular population within an organism characterized by dysregulated growth and the ability to bypass normal physiological constraints on cell division and survival (National Cancer Institute, 2023). These cells originate from the host's own tissues through a process of oncogenic transformation driven by genetic mutations and epigenetic changes that lead to the 'hallmarks of cancer,' including sustained proliferative signaling and evasion of growth suppressors (Hanahan & Weinberg, 2011). In the context of pharmacology, while these cells are the ultimate destination for anti-cancer therapies, the term itself refers to a complex biological system or cell type rather than a single molecular target like a receptor or enzyme. Treatment modalities such as chemotherapy, radiotherapy, and immunotherapy aim to selectively eliminate these cells while sparing normal host tissue, though this remains a significant challenge due to the biological similarities between tumor and healthy cells (American Cancer Society, 2024). The study of host tumor cells involves understanding their metabolic needs, signaling pathways, and interactions with the surrounding tumor microenvironment to identify specific molecular vulnerabilities for drug development (Mayo Clinic, 2024).

Other names

Cancer cellsMalignant cellsNeoplastic cellsTumor cells

Drugs targeting host tumor cells typically act by inducing direct cytotoxicity through DNA damage or mitotic inhibition, blocking specific oncogenic signaling pathways (e.g., kinase inhibition), or modulating the immune system to recognize and destroy malignant cells via checkpoint blockade (NIH, 2023).